TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 avr. 2024 09h10 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update